Literature DB >> 23524187

Immune system targeting by biodegradable nanoparticles for cancer vaccines.

Joana M Silva1, Mafalda Videira, Rogério Gaspar, Véronique Préat, Helena F Florindo.   

Abstract

The concept of therapeutic cancer vaccines is based on the activation of the immune system against tumor cells after the presentation of tumor antigens. Nanoparticles (NPs) have shown great potential as delivery systems for cancer vaccines as they potentiate the co-delivery of tumor-associated antigens and adjuvants to dendritic cells (DCs), insuring effective activation of the immune system against tumor cells. In this review, the immunological mechanisms behind cancer vaccines, including the role of DCs in the stimulation of T lymphocytes and the use of Toll-like receptor (TLR) ligands as adjuvants will be discussed. An overview of each of the three essential components of a therapeutic cancer vaccine - antigen, adjuvant and delivery system - will be provided with special emphasis on the potential of particulate delivery systems for cancer vaccines, in particular those made of biodegradable aliphatic polyesters, such as poly(lactic-co-glycolic acid) (PLGA) and poly-ε-caprolactone (PCL). Some of the factors that can influence NP uptake by DCs, including size, surface charge, surface functionalization and route of administration, will also be considered.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23524187     DOI: 10.1016/j.jconrel.2013.03.010

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  49 in total

Review 1.  Applications of nanomaterials as vaccine adjuvants.

Authors:  Motao Zhu; Rongfu Wang; Guangjun Nie
Journal:  Hum Vaccin Immunother       Date:  2014-11-17       Impact factor: 3.452

Review 2.  Biomaterials for vaccine-based cancer immunotherapy.

Authors:  Rui Zhang; Margaret M Billingsley; Michael J Mitchell
Journal:  J Control Release       Date:  2018-10-09       Impact factor: 9.776

3.  α-Galactosylceramide and peptide-based nano-vaccine synergistically induced a strong tumor suppressive effect in melanoma.

Authors:  Vanessa Sainz; Liane I F Moura; Carina Peres; Ana I Matos; Ana S Viana; Angela M Wagner; Julia E Vela Ramirez; Teresa S Barata; Manuela Gaspar; Steve Brocchini; Mire Zloh; Nicholas A Peppas; Ronit Satchi-Fainaro; Helena F Florindo
Journal:  Acta Biomater       Date:  2018-06-22       Impact factor: 8.947

4.  Three steps to breaking immune tolerance to lymphoma: a microparticle approach.

Authors:  Amani Makkouk; Vijaya B Joshi; Caitlin D Lemke; Amaraporn Wongrakpanich; Alicia K Olivier; Sue E Blackwell; Aliasger K Salem; George J Weiner
Journal:  Cancer Immunol Res       Date:  2015-01-27       Impact factor: 11.151

Review 5.  Functional and Biomimetic Materials for Engineering of the Three-Dimensional Cell Microenvironment.

Authors:  Guoyou Huang; Fei Li; Xin Zhao; Yufei Ma; Yuhui Li; Min Lin; Guorui Jin; Tian Jian Lu; Guy M Genin; Feng Xu
Journal:  Chem Rev       Date:  2017-10-09       Impact factor: 60.622

Review 6.  Potential applications of nanoparticles in cancer immunotherapy.

Authors:  Yimei Jia; Abdelwahab Omri; Lakshmi Krishnan; Michael J McCluskie
Journal:  Hum Vaccin Immunother       Date:  2016-11-21       Impact factor: 3.452

7.  Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma.

Authors:  Motao Zhu; Xilai Ding; Ruifang Zhao; Xuewu Liu; Haifa Shen; Chunmei Cai; Mauro Ferrari; Helen Y Wang; Rong-Fu Wang
Journal:  J Control Release       Date:  2018-01-08       Impact factor: 9.776

Review 8.  Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment.

Authors:  Yunlu Dai; Can Xu; Xiaolian Sun; Xiaoyuan Chen
Journal:  Chem Soc Rev       Date:  2017-05-18       Impact factor: 54.564

Review 9.  Dendritic cell therapy in melanoma.

Authors:  Carmen Alvarez-Dominguez; Ricardo Calderón-Gonzalez; Hector Terán-Navarro; David Salcines-Cuevas; Almudena Garcia-Castaño; Javier Freire; Javier Gomez-Roman; Fernando Rivera
Journal:  Ann Transl Med       Date:  2017-10

Review 10.  Current challenges for cancer vaccine adjuvant development.

Authors:  William S Bowen; Abhishek K Svrivastava; Lalit Batra; Hampartsoum Barsoumian; Haval Shirwan
Journal:  Expert Rev Vaccines       Date:  2018-02-08       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.